Atai Life Sciences NV (ATAI) News & Sentiment

- Elumina is a Phase 2, multicenter, double-blind, randomized, placebo-controlled, clinical trial to assess the efficacy, safety and tolerability of VLS-01 (buccal film DMT) in people suffering from treatment-resistant depression

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced that patient enrollment has been completed in Beckley Psytech's Phase 2b trial evaluating BPL-003 in treatment-resistant depression (TRD), with topline results expected by mid-2025. The trial is assessing the efficacy and safety of a single dose of BPL-003, an intranasal formulation of mebufotenin benzoate developed by Beckley Psytech, in which atai is invested, designed for rapid and lasting antidepressant effects with minimal clinic time.

Jason Najum talks to Srinivas Rao, CEO of Atai Life Sciences, a biotech company focused on mental health and psychedelic compounds. Standing on the shoulders of Johnson & Johnson's Spravato.

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced that it has closed is public offering of shares and the underwriter's option to purchase additional shares for gross proceeds of approximately $63.25 million before deductions. The company, a clinical-stage biopharmaceutical company focused on mental health treatments, offered about 26.2 million common shares for $2.10 per share, with the underwriter's purchasing an additional 3.9 million shares.

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) said its registered underwritten offering of approximately 26.2 million shares will be priced at $2.10 per share to raise proceeds of $55 million. The underwriter has a 30-day option to purchase up to an additional approximately 3.9 million shares.

NEW YORK and BERLIN, Feb. 12, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health disorders, today announced the pricing of a registered underwritten offering of 26,190,477 common shares, at a price of $2.10 per share. atai has granted the underwriter a 30-day option to purchase up to an additional 3,928,571 common shares. All common shares to be sold in the offering will be sold by atai.

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) has announced a proposed underwritten public offering of $55 million of its common shares. The company may also grant the underwriter a 30-day option to purchase up to an additional $8.25 million in shares, it said in a statement after Wednesday's closing bell.

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) CEO Dr. Srinivas Rao joined Proactive to discuss promising results from Beckley Psytech's Phase 2a trial for BPL-003 in alcohol use disorder.

As psychedelics stocks trade higher following the release of positive data for GH Research's 5-MeO-DMT drug for treatment-resistant depression, analysts at Jefferies believe Beckley Psytech's intranasal 5-MeO-DMT candidate BPL-003 could have an even better value proposition. This could have a positive readthrough for atai Life Sciences (NASDAQ:ATAI, ETR:9VC), an investor in Beckley.